Evidence map›Paper›PMID 27481317›Full record

ArticleScientific reports2016

Protein Inhibitor of NOS1 Plays a Central Role in the Regulation of NOS1 Activity in Human Dilated Hearts.

Esther Roselló-Lletí, Estefanía Tarazón, Ana Ortega, Carolina Gil-Cayuela, Ricardo Carnicer, Francisca Lago, Jose Ramón González-Juanatey, Manuel Portolés, Miguel Rivera

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Esther Roselló-LletíCardiocirculatory Unit, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain.
Estefanía TarazónCardiocirculatory Unit, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain.
Ana OrtegaCardiocirculatory Unit, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain.
Carolina Gil-CayuelaCardiocirculatory Unit, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain.
Ricardo CarnicerDepartment of Cardiovascular Medicine, University of Oxford, United Kingdom.
Francisca LagoCellular and Molecular Cardiology Research Unit, Department of Cardiology and Institute of Biomedical Research, University Clinical Hospital, Santiago de Compostela, Spain.
Jose Ramón González-JuanateyCellular and Molecular Cardiology Research Unit, Department of Cardiology and Institute of Biomedical Research, University Clinical Hospital, Santiago de Compostela, Spain.
Manuel PortolésCardiocirculatory Unit, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain.
Miguel RiveraCardiocirculatory Unit, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain.
Instituto de Investigación Sanitaria La Fe · ESUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An essential factor for the production of nitric oxide by nitric oxide synthase 1 (NOS1), major modulator of cardiac function, is the cofactor tetrahydrobiopterin (BH4). BH4 is regulated by GTP cyclohydrolase 1, the rate-limiting enzyme in BH4 biosynthesis which catalyses the formation of dihydroneopterin 3'triphosfate from GTP, producing BH4 after two further steps catalyzed by 6-pyruvoyltetrahydropterin synthase and sepiapterin reductase. However, there are other essential factors involved in the regulation of NOS1 activity, such as protein inhibitor of NOS1 (PIN), calmodulin, heat shock protein 90, and NOS interacting protein. All these molecules have never been analysed in human non-ischemic dilated hearts (DCM). In this study we demonstrated that the upregulation of cardiac NOS1 is not accompanied by increased NOS1 activity in DCM, partly due to the elevated PIN levels and not because of alterations in biopterin biosynthesis. Notably, the PIN concentration was significantly associated with impaired ventricular function, highlighting the importance of this NOS1 activity inhibitor in Ca(2+) homeostasis. These results take a central role in the current list of targets for future studies focused on the complex cardiac dysfunction processes through more efficient harnessing of NOS1 signalling.

Indexed as

BiomarkersBiopterinsCardiomyopathy, DilatedCase-Control StudiesCytoplasmic DyneinsFemaleHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedNitric Oxide Synthase Type IBiomarkersBiopterinsCytoplasmic DyneinsDYNLL1 protein, humanNitric Oxide Synthase Type INOS1 protein, humansapropterin

Identifiers

PMID27481317
PMCPMC4969592
OpenAlexW2492313821

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.